NYSE:GBS GBS (GBS) Stock Forecast, Price & News $2.82 +0.02 (+0.72%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$2.73▼$2.9050-Day Range$0.47▼$3.4252-Week Range$0.36▼$2.89Volume25,935 shsAverage Volume955,325 shsMarket Capitalization$41.92 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media About GBS (NYSE:GBS) StockGBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.Read More Receive GBS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GBS and its competitors with MarketBeat's FREE daily newsletter. Email Address GBS Stock News HeadlinesJune 4, 2023 | msn.comSignalling issue, why no Kavach: Odisha train tragedy decodedJune 3, 2023 | msn.comBungo Stray Dogs Receives Season 5 Release Date And TrailerJune 4, 2023 | Stocks To Trade (Ad)15 A.I. Trading Opportunities a DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.June 2, 2023 | msn.com'It has been a nightmare': Boise dad pleas for help as his daughter is in an ICU in GermanyJune 1, 2023 | finance.yahoo.comEnable Medicine Unveils Generative Biological Search, A First Step Towards the Future of Research in Science and MedicineMay 30, 2023 | finance.yahoo.comAsia Pacific Medical Aesthetics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product Type, Application, and End UserMay 27, 2023 | msn.comAfter plaint, HC bar association decides to boycott Court of Justice KshetarpalMay 25, 2023 | mirror.co.uk'I feared being labelled 'the angry Black woman' - but 5 weeks later my baby was dead'June 4, 2023 | Stocks To Trade (Ad)15 A.I. Trading Opportunities a DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 25, 2023 | mirror.co.ukYou could win a Weber Spirit Premium Gas Barbecue in time for the summerMay 24, 2023 | americanbankingnews.comAnalyzing Tenon Medical (NASDAQ:TNON) & GBS (NYSE:GBS)May 19, 2023 | markets.businessinsider.comA Global ETF For Stock Investors Looking To Support Democracies Over Authoritarian RegimesMay 18, 2023 | seekingalpha.comDXC Technology Non-GAAP EPS of $1.02 misses by $0.02, revenue of $3.59B misses by $30MMay 18, 2023 | msn.comEverything You Need To Know About The ROG AllyMay 18, 2023 | msn.comNagaland: Children of non-Naga fathers, non-Naga children adopted by Naga parents cannot claim ST statusMay 18, 2023 | msn.comVoices: Kate Winslet is right – we’ve killed off the age of innocence with social mediaMay 17, 2023 | msn.comVerizon's New Phone Plan Is Completely Customizable and Packs Some Serious ValueMay 10, 2023 | marketwatch.comGroup B Streptococcus (GBS) Infection Treatment MarketMay 5, 2023 | msn.comNW200: Dominic Herbertson joins Jeremy McWilliams in Wilson Craig Racing line-upMay 5, 2023 | msn.comNo Decision Yet On Monday Classes After Glenbrook South Fire: OfficialMay 5, 2023 | msn.comFDA approves first RSV vaccine, shots to be available for older adultsMay 4, 2023 | markets.businessinsider.comModerna Reports First Quarter 2023 Financial Results and Provides Business UpdatesMay 4, 2023 | msn.comIn Historic Decision, FDA Approves World’s First RSV VaccineMay 3, 2023 | msn.comTeacher at Chartiers Valley surprised with donation to Guillain-Barre foundationMay 3, 2023 | msn.comTeacher surprised with donation to Guillain-Barre foundationMay 3, 2023 | msn.comFDA approves first-ever RSV vaccine, shots to be available for older adultsMay 3, 2023 | news.yahoo.comKids of Steel: Chartiers Valley students surprise teacher with donation to GBS FoundationSee More Headlines GBS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GBS Company Calendar Last Earnings8/31/2022Today6/03/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNYSE:GBS CUSIPN/A CIK1725430 Webwww.gbs.inc Phone646 828 8258FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,310,000.00 Net MarginsN/A Pretax Margin-1,907.09% Return on Equity-85.64% Return on Assets-54.42% Debt Debt-to-Equity RatioN/A Current Ratio2.33 Quick Ratio2.33 Sales & Book Value Annual Sales$440,000.00 Price / Sales95.27 Cash FlowN/A Price / Cash FlowN/A Book Value$0.44 per share Price / Book6.40Miscellaneous Outstanding Shares14,890,000Free Float14,850,000Market Cap$41.92 million OptionableNot Optionable Beta1.32 Key ExecutivesDr. Stephen Constantine Boyages M.D. (Age 64)MBBS, Ph.D., Interim CEO & Chairman Comp: $85.64kMr. Spiro Kevin Sakiris B.Bus (Age 60)C.A., CA, Dip Law, Chief Financial Officer Comp: $292.45kMr. Harry Simeonidis (Age 53)Pres of Asia Pacific Comp: $354.71kMs. Victoria Gavrilenko (Age 39)Operations Mang. Mr. Alex ArzenoVP of Investor RelationsKey CompetitorsSensus HealthcareNASDAQ:SRTSPAVmedNASDAQ:PAVMIceCure MedicalNASDAQ:ICCMLENSARNASDAQ:LNSRMinerva SurgicalNASDAQ:UTRSView All CompetitorsInsidersSpiro Kevin SakirisBought 5,000 shares on 6/22/2022Total: $3,250.00 ($0.65/share)Spiro Kevin SakirisBought 15,970 shares on 6/17/2022Total: $9,741.70 ($0.61/share)View All Insider Transactions GBS Stock - Frequently Asked Questions How have GBS shares performed in 2023? GBS's stock was trading at $0.1999 on January 1st, 2023. Since then, GBS stock has increased by 1,308.4% and is now trading at $2.8153. View the best growth stocks for 2023 here. How were GBS's earnings last quarter? GBS Inc. (NYSE:GBS) released its earnings results on Wednesday, August, 31st. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.04. What is GBS's stock symbol? GBS trades on the New York Stock Exchange (NYSE) under the ticker symbol "GBS." How do I buy shares of GBS? Shares of GBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is GBS's stock price today? One share of GBS stock can currently be purchased for approximately $2.82. How much money does GBS make? GBS (NYSE:GBS) has a market capitalization of $41.92 million and generates $440,000.00 in revenue each year. The company earns $-8,310,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. How can I contact GBS? The official website for the company is www.gbs.inc. The company can be reached via phone at 646 828 8258 or via email at investor.relations@gbs.inc. This page (NYSE:GBS) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GBS Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.